{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T02:35:03Z","timestamp":1772073303506,"version":"3.50.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T00:00:00Z","timestamp":1332460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0034354","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T06:29:51Z","timestamp":1332570591000},"page":"e34354","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rational Design and Characterization of D-Phe-Pro-D-Arg-Derived Direct Thrombin Inhibitors"],"prefix":"10.1371","volume":"7","author":[{"given":"Ana C.","family":"Figueiredo","sequence":"first","affiliation":[]},{"given":"Cristina C.","family":"Clement","sequence":"additional","affiliation":[]},{"given":"Sheuli","family":"Zakia","sequence":"additional","affiliation":[]},{"given":"Julian","family":"Gingold","sequence":"additional","affiliation":[]},{"given":"Manfred","family":"Philipp","sequence":"additional","affiliation":[]},{"given":"Pedro J. B.","family":"Pereira","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2012,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-1-60761-803-4_5","article-title":"Novel anticoagulant therapy: principle and practice.","volume":"663","author":"SA Mousa","year":"2010","journal-title":"Methods Mol Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/eurheartj\/ehr052","article-title":"Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.","volume":"32","author":"J Steffel","year":"2011","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2459\/JCM.0b013e32832edac0","article-title":"Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.","volume":"10","author":"J Steffel","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/med.20016","article-title":"Progress in the design of low molecular weight thrombin inhibitors.","volume":"25","author":"S Srivastava","year":"2005","journal-title":"Med Res Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/j.1460-2075.1989.tb08511.x","article-title":"The refined 1.9 \u00c5 crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment.","volume":"8","author":"W Bode","year":"1989","journal-title":"EMBO J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4899-2418-6_16","article-title":"The synthesis and anticoagulant activity of novel peptidylfluoroalkanes.","volume":"340","author":"B Neises","year":"1993","journal-title":"Adv Exp Med Biol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.","volume":"29","author":"JM Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0022-2836(91)90939-4","article-title":"Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.","volume":"221","author":"E Skrzypczak-Jankun","year":"1991","journal-title":"J Mol Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1016\/S0021-9258(18)54894-8","article-title":"Crystallographic analysis at 3.0-\u00c5 resolution of the binding to human thrombin of four active site-directed inhibitors.","volume":"266","author":"DW Banner","year":"1991","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","article-title":"Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.","volume":"101","author":"S Okamoto","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11239-011-0569-6","article-title":"Heparin-induced thrombocytopenia: present and future.","volume":"31","author":"A Cuker","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"ref12","first-page":"813","article-title":"Argatroban in the management of heparin-induced thrombocytopenia.","volume":"6","author":"L Babuin","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.","volume":"47","author":"J Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10840-011-9593-x","article-title":"Dabigatran in atrial fibrillation: pharmacology and clinical trials.","volume":"32","author":"M Ezekowitz","year":"2011","journal-title":"J Interv Card Electrophysiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure-based design of novel potent nonpeptide thrombin inhibitors.","volume":"45","author":"NH Hauel","year":"2002","journal-title":"J Med Chem"},{"key":"ref16","first-page":"16","article-title":"Design and synthesis of peptide inhibitors of blood coagulations.","volume":"109","author":"S Bajusz","year":"1982","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1538-7836.2008.02937.x","article-title":"Thrombostatin FM compounds: direct thrombin inhibitors \u2013 mechanism of action <italic>in vitro<\/italic> and <italic>in vivo<\/italic>.","volume":"6","author":"MT Nieman","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/jpet.104.069229","article-title":"The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.","volume":"311","author":"MT Nieman","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1747-0285.2006.00442.x","article-title":"Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.","volume":"68","author":"FM Burke","year":"2006","journal-title":"Chem Biol Drug Des"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1747-0285.2009.00915.x","article-title":"Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.","volume":"75","author":"EA Girnys","year":"2010","journal-title":"Chem Biol Drug Des"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bmcl.2010.12.105","article-title":"Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors.","volume":"21","author":"RCA Isaacs","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156802609789207127","article-title":"Structure-based drug design strategies in medicinal chemistry.","volume":"9","author":"AD Andricopulo","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/156802610790232251","article-title":"Successful applications of computer aided drug discovery: moving drugs from concept to the clinic.","volume":"10","author":"TT Talele","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1073\/pnas.91.21.9765","article-title":"Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics.","volume":"91","author":"G Guichard","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"11689","DOI":"10.1021\/bi00162a004","article-title":"Structure of the hirulog 3-thrombin complex and nature of the S\u2032 subsites of substrates and inhibitors.","volume":"31","author":"X Qiu","year":"1992","journal-title":"Biochemistry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1107\/S1744309110043472","article-title":"Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with \u03b1-thrombin.","volume":"67","author":"AC Figueiredo","year":"2011","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software.","volume":"40","author":"AJ McCoy","year":"2007","journal-title":"J Appl Crystallogr"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/hlca.200490225","article-title":"Enantiomerically pure thrombin inhibitors for exploring the molecular-recognition features of the oxyanion hole.","volume":"87","author":"K Sch\u00e4rer","year":"2004","journal-title":"Helv Chim Acta"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics.","volume":"60","author":"P Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution.","volume":"66","author":"PD Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1107\/S0907444906005270","article-title":"Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.","volume":"62","author":"J Painter","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1107\/S0021889805038987","article-title":"TLSMD web server for the generation of multi-group TLS models.","volume":"39","author":"J Painter","year":"2006","journal-title":"J Appl Cryst"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e19969","DOI":"10.1371\/journal.pone.0019969","article-title":"New synthetic thrombin inhibitors: molecular design and experimental verification.","volume":"6","author":"EI Sinauridze","year":"2011","journal-title":"PLoS ONE"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pro.5560010402","article-title":"The refined 1.9-\u00c5 X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.","volume":"1","author":"W Bode","year":"1992","journal-title":"Protein Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/jm981013e","article-title":"Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors.","volume":"41","author":"J Wagner","year":"1998","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1006\/jmbi.2001.5394","article-title":"The methyl group of N[alpha](Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.","volume":"316","author":"R Friedrich","year":"2002","journal-title":"J Mol Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1006\/jmbi.1997.1037","article-title":"Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: A kinetic, thermodynamic and X-ray crystallographic study.","volume":"269","author":"G De Simone","year":"1997","journal-title":"J Mol Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/abbi.1995.1452","article-title":"Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 \u00c5 resolution.","volume":"322","author":"ZG Chen","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/pro.5560050303","article-title":"Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic.","volume":"5","author":"R Krishnan","year":"1996","journal-title":"Protein Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/S0006-3495(96)79479-1","article-title":"Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1\u2032 binding site.","volume":"71","author":"JH Matthews","year":"1996","journal-title":"Biophys J"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1021\/jm980052n","article-title":"Bound structures of novel P3\u2013P1\u2032 beta-strand mimetic inhibitors of thrombin.","volume":"42","author":"R St Charles","year":"1999","journal-title":"J Med Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/bi992419b","article-title":"Design of P1\u2032 and P3\u2032 residues of trivalent thrombin inhibitors and their crystal structures.","volume":"39","author":"JJ Slon-Usakiewicz","year":"2000","journal-title":"Biochemistry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0034354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T02:09:26Z","timestamp":1641521366000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0034354"}},"subtitle":[],"editor":[{"given":"Monika","family":"Oberer","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2012,3,23]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0034354","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,23]]}}}